Amgen To Acquire Privately Held Teneobio For $900 Million In Cash With Future Contingent Milestone Payments
The Pharma Data
JULY 27, 2021
Amgen (NASDAQ: AMGN) and Teneobio today announced an agreement under which Amgen will acquire Teneobio, a privately held, clinical stage biotechnology company developing a new class of biologics called Human Heavy-Chain Antibodies. executive vice president of Research and Development at Amgen. billion in cash. Reese, M.D.,
Let's personalize your content